View ValuationSureNano Science 将来の成長Future 基準チェック /06現在、 SureNano Scienceの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Trade Distributors 収益成長14.8%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • May 16+ 1 more updateSurenano Science Ltd. Announces Distinct Next-Generation Glp-1 Platform Built Around Novel PeptideSureNano Science Ltd. has developed a distinct next-generation GLP-1 platform built around GEP-44, a novel triple agonist peptide engineered to improve efficacy, tolerability, and delivery flexibility within one of the most commercially dynamic pharmaceutical markets in history. SureNano Science Ltd. has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential noninjectable delivery. The initial business of SureNano Science Ltd. is the sale and distribution of the SureNano(TM) surfactant, which is a ready-to-mix food grade compound that provides the base for high performance nanoemulsions to create incredibly homogeneous and stable products while maximizing bioavailability, clarity, and taste. The Company has an exclusive license to distribute the SureNano(TM) surfactant within Canada; Oklahoma, USA; and Colorado, USA. SureNano Science Ltd. is now developing into a pharmaceutical focused company through the advancement of a patented therapeutic candidate designed to address obesity and metabolic disease.Board Change • Mar 02Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Doug Bachman was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Feb 18New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 58% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Market cap is less than US$10m (CA$10.2m market cap, or US$7.45m).お知らせ • Dec 10SureNano Science Ltd. announced that it has received CAD 1.25 million in fundingOn December 10, 2025, SureNano Science Ltd. closed the transaction. In connection with the private placement, the company paid cash commissions of CAD 75,000 and issued an aggregate of 600,000 finder's warrants to certain brokerage firms and agents for introducing subscribers to the company. Each finder's warrant entitles the holder to receive one common share in the capital of the company at a price of CAD 0.35 per common share for a period of 24 months from the date of issuance, subject to the acceleration provision.お知らせ • Nov 06SureNano Science Ltd. announced that it expects to receive CAD 1.25 million in fundingSureNano Science Ltd. announced a private placement of up to 10,000,000 units at a price of CAD 0.125 per unit for proceeds of up to CAD 1,250,000 on November 5, 2025. Each unit will be comprised of one common share and one common share purchase warrant, with each warrant entitling the holder thereof to acquire one common share in the capital of the company at a price of CAD 0.35 per common share for a period of 24 months from the date of issuance. In consideration for their services in introducing subscribers to the company under the private placement, finders may receive commission of 6% cash and 6% common share purchase warrants, exercisable to purchase one common share at a price of CAD 0.35 for a period of 24 months. All securities issued in the private placement will be subject to a four month and a day hold period.お知らせ • Aug 22SureNano Science Ltd. announced that it expects to receive CAD 0.215 million in fundingSureNano Science Ltd. announced a private placement to issue 2,100,000 common shares at an issue price of CAD 0.10 per share for gross proceeds of CAD 215,000 on August 22, 2025. All securities issued in the private placement will be subject to a four month and a day hold period. . Up to 3,000,000 Private Placement and Debt Settlement shares in total be issued at a price of $0.10 per share subject to CSE approval.お知らせ • Jun 10SureNano Science Ltd., Annual General Meeting, Aug 08, 2025SureNano Science Ltd., Annual General Meeting, Aug 08, 2025.お知らせ • Nov 21SureNano Science Ltd., Annual General Meeting, Feb 09, 2024SureNano Science Ltd., Annual General Meeting, Feb 09, 2024.お知らせ • Nov 25SureNano Science Ltd. Approves Board ChangesSureNano Science Ltd. at its annual general and special meeting held on November 24, 2022, approved to elect Doug Bachman as a new member of the Company's board of Directors. Mr. Bachman is currently a director of Rebel Capital 2.0 Corp. Mr. Bachman also acts as a consultant advising private and public companies on M&A activity. Mr. Bachman brings more than 25 years' experience of Corporate Finance and Management from a major financial institution. This experience has provided him with extensive knowledge in credit, wealth management, team building and leadership. Mark Scott has stepped down from his role as Director.お知らせ • Sep 13SureNano Science Ltd., Annual General Meeting, Nov 24, 2022SureNano Science Ltd., Annual General Meeting, Nov 24, 2022. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、SureNano Science は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CNSX:SURE - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数アナリストによる今後の成長予測収入対貯蓄率: SUREの予測収益成長が 貯蓄率 ( 3% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: SUREの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: SUREの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: SUREの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: SUREの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: SUREの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YCapital-goods 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/18 10:19終値2026/06/12 00:00収益N/A年間収益N/Aデータソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋SureNano Science Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • May 16+ 1 more updateSurenano Science Ltd. Announces Distinct Next-Generation Glp-1 Platform Built Around Novel PeptideSureNano Science Ltd. has developed a distinct next-generation GLP-1 platform built around GEP-44, a novel triple agonist peptide engineered to improve efficacy, tolerability, and delivery flexibility within one of the most commercially dynamic pharmaceutical markets in history. SureNano Science Ltd. has acquired GlucaPharm Inc., a next-generation GLP-1 pharmaceutical company developing GEP44, a patented peptide targeting obesity and metabolic disorders with improved tolerability and potential noninjectable delivery. The initial business of SureNano Science Ltd. is the sale and distribution of the SureNano(TM) surfactant, which is a ready-to-mix food grade compound that provides the base for high performance nanoemulsions to create incredibly homogeneous and stable products while maximizing bioavailability, clarity, and taste. The Company has an exclusive license to distribute the SureNano(TM) surfactant within Canada; Oklahoma, USA; and Colorado, USA. SureNano Science Ltd. is now developing into a pharmaceutical focused company through the advancement of a patented therapeutic candidate designed to address obesity and metabolic disease.
Board Change • Mar 02Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Doug Bachman was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Feb 18New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 58% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Shareholders have been substantially diluted in the past year (58% increase in shares outstanding). Market cap is less than US$10m (CA$10.2m market cap, or US$7.45m).
お知らせ • Dec 10SureNano Science Ltd. announced that it has received CAD 1.25 million in fundingOn December 10, 2025, SureNano Science Ltd. closed the transaction. In connection with the private placement, the company paid cash commissions of CAD 75,000 and issued an aggregate of 600,000 finder's warrants to certain brokerage firms and agents for introducing subscribers to the company. Each finder's warrant entitles the holder to receive one common share in the capital of the company at a price of CAD 0.35 per common share for a period of 24 months from the date of issuance, subject to the acceleration provision.
お知らせ • Nov 06SureNano Science Ltd. announced that it expects to receive CAD 1.25 million in fundingSureNano Science Ltd. announced a private placement of up to 10,000,000 units at a price of CAD 0.125 per unit for proceeds of up to CAD 1,250,000 on November 5, 2025. Each unit will be comprised of one common share and one common share purchase warrant, with each warrant entitling the holder thereof to acquire one common share in the capital of the company at a price of CAD 0.35 per common share for a period of 24 months from the date of issuance. In consideration for their services in introducing subscribers to the company under the private placement, finders may receive commission of 6% cash and 6% common share purchase warrants, exercisable to purchase one common share at a price of CAD 0.35 for a period of 24 months. All securities issued in the private placement will be subject to a four month and a day hold period.
お知らせ • Aug 22SureNano Science Ltd. announced that it expects to receive CAD 0.215 million in fundingSureNano Science Ltd. announced a private placement to issue 2,100,000 common shares at an issue price of CAD 0.10 per share for gross proceeds of CAD 215,000 on August 22, 2025. All securities issued in the private placement will be subject to a four month and a day hold period. . Up to 3,000,000 Private Placement and Debt Settlement shares in total be issued at a price of $0.10 per share subject to CSE approval.
お知らせ • Jun 10SureNano Science Ltd., Annual General Meeting, Aug 08, 2025SureNano Science Ltd., Annual General Meeting, Aug 08, 2025.
お知らせ • Nov 21SureNano Science Ltd., Annual General Meeting, Feb 09, 2024SureNano Science Ltd., Annual General Meeting, Feb 09, 2024.
お知らせ • Nov 25SureNano Science Ltd. Approves Board ChangesSureNano Science Ltd. at its annual general and special meeting held on November 24, 2022, approved to elect Doug Bachman as a new member of the Company's board of Directors. Mr. Bachman is currently a director of Rebel Capital 2.0 Corp. Mr. Bachman also acts as a consultant advising private and public companies on M&A activity. Mr. Bachman brings more than 25 years' experience of Corporate Finance and Management from a major financial institution. This experience has provided him with extensive knowledge in credit, wealth management, team building and leadership. Mark Scott has stepped down from his role as Director.
お知らせ • Sep 13SureNano Science Ltd., Annual General Meeting, Nov 24, 2022SureNano Science Ltd., Annual General Meeting, Nov 24, 2022.